Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS)
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals Hold Rating: Navigating Syfovre’s Mixed Reception and Emerging Competition
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS)
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
Insider Sell: Chief Business & Strategy Officer Mark Delong Sells 9,913 Shares of Apellis ...
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE)
Apellis Pharmaceuticals Inc (APLS) CTO Nur Nicholson Sells 11,220 Shares
Apellis Pharmaceuticals Inc's Chief Scientific Officer Pascal Deschatelets Sells 69,107 Shares
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Analysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Apellis Pharmaceuticals (APLS) and Iovance Biotherapeutics (IOVA)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.